BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Diabetes mellitus
,
Pancreas
,
Alcohol
,
Lovastatin
,
rs2230926
,
NEUROG3
,
Coagulation
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
imd0354
(compound)
Summary
General Info
Genetic Markers
Most Correlated Genes
ZBP1
IFITM1
EGR2
BST2
IFIT3
Explore Genetic Markers Results
Pathway Enrichment
Most Correlated Biogroups
TRAVAGLINI_LUNG_PROLIFERATING_BASAL_CELL
TRAVAGLINI_LUNG_PROLIFERATING_MACROPHAGE_CELL
HAY_BONE_MARROW_ERYTHROBLAST
DIAZ_CHRONIC_MEYLOGENOUS_LEUKEMIA_UP
cytosol
Explore Pathway Enrichment Results
Curated Studies
Most Correlated Studies
Lung adenocarcinoma Calu-3 cells infected with SARS-CoV-2 and treated or untreated with IMD-0354
Explore Curated Studies Results
Literature
Most Relevant Literature
Identification and Characterization of IMD-0354 as a Glutamine Carrier Protein Inhibitor in Melanoma…
Antiviral activities of mycophenolic acid and IMD-0354 against SARS-CoV-2.
Structure-Function Studies on IMD-0354 Identifies Highly Active Colistin Adjuvants.
The emerging role of IMD 0354 on bone homeostasis by suppressing osteoclastogenesis and bone resorpt…
Anti-cancer activity of the novel 2-hydroxydiarylamide derivatives IMD-0354 and KRT1853 through supp…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
There were no clinical trials for imd0354
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ